WO2009041566A1 - キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 - Google Patents

キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 Download PDF

Info

Publication number
WO2009041566A1
WO2009041566A1 PCT/JP2008/067405 JP2008067405W WO2009041566A1 WO 2009041566 A1 WO2009041566 A1 WO 2009041566A1 JP 2008067405 W JP2008067405 W JP 2008067405W WO 2009041566 A1 WO2009041566 A1 WO 2009041566A1
Authority
WO
WIPO (PCT)
Prior art keywords
posterior eye
derivative
remedy
preventive
group
Prior art date
Application number
PCT/JP2008/067405
Other languages
English (en)
French (fr)
Inventor
Sayo Habashita
Shin-Ichiro Hirai
Yoshiki Ohashi
Masaaki Sasaoka
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of WO2009041566A1 publication Critical patent/WO2009041566A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

　一般式（I）で表される化合物又はその塩は、脈絡膜や網膜といった後眼部組織において、優れた血管新生阻害作用、血管透過性亢進抑制作用及び網膜神経細胞保護作用を有するので、加齢黄斑変性、糖尿病網膜症、糖尿病黄斑浮腫、緑内障性視野狭窄などの後眼部疾患の予防又は治療剤として有用である。式中、Ａ１－Ａ２は基１を示し、Ｘは基２等を示し、Ｙは炭素原子又は窒素原子を示し、破線は単結合又は二重結合を示し、Ｌは単結合、アルキレン基、シクロアルケニレン基等を示し、Ｒ１ａとＲ１ｂは同一又は異なって水素原子、ハロゲン原子等を示し、Ｒ２は水素原子又はハロゲン原子を示し、Ｒ３は水素原子又はハロゲン原子を示す。 　　【化１】
PCT/JP2008/067405 2007-09-26 2008-09-26 キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 WO2009041566A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-249365 2007-09-26
JP2007249365 2007-09-26

Publications (1)

Publication Number Publication Date
WO2009041566A1 true WO2009041566A1 (ja) 2009-04-02

Family

ID=40511446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067405 WO2009041566A1 (ja) 2007-09-26 2008-09-26 キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤

Country Status (2)

Country Link
JP (1) JP2009196973A (ja)
WO (1) WO2009041566A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008872A1 (ja) 2011-07-13 2013-01-17 参天製薬株式会社 Ｐａｒｐ阻害活性を有する新規化合物
CN104761506A (zh) * 2015-04-10 2015-07-08 温州大学 一种2-(1-苯乙烯基)喹唑啉酮化合物及其合成方法
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
US10034880B2 (en) 2014-09-11 2018-07-31 Sumitomo Dainippon Pharma Co., Ltd. Ophthalmic suspension formulation
RU2815480C1 (ru) * 2019-10-30 2024-03-18 Даимбайо. Инк. Производные изохинолинона, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с поли(АДФ-рибоза)полимеразой-1, содержащая их в качестве активного ингредиента

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396004A4 (en) * 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
KR102030016B1 (ko) * 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
JP2023506368A (ja) * 2019-10-30 2023-02-16 ディグムバイオ．インコーポレイテッド イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077197A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 47 human secreted proteins
WO2002048711A1 (fr) * 2000-12-11 2002-06-20 Iatron Laboratories, Inc. Reactifs d'analyse immunologique et procede d'analyse
JP2002284699A (ja) * 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003055865A1 (en) * 2001-12-24 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
WO2003063874A1 (en) * 2002-01-29 2003-08-07 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors
WO2005009398A2 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
WO2005082079A2 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Tetracyclic lactam derivatives and uses thereof
WO2006079478A1 (en) * 2005-01-25 2006-08-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. 2-phenylquinoxalines as inhibitors for mpp1

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077197A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 47 human secreted proteins
WO2002048711A1 (fr) * 2000-12-11 2002-06-20 Iatron Laboratories, Inc. Reactifs d'analyse immunologique et procede d'analyse
JP2002284699A (ja) * 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003055865A1 (en) * 2001-12-24 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
WO2003063874A1 (en) * 2002-01-29 2003-08-07 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors
WO2005009398A2 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
WO2005082079A2 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Tetracyclic lactam derivatives and uses thereof
WO2006079478A1 (en) * 2005-01-25 2006-08-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. 2-phenylquinoxalines as inhibitors for mpp1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MIKI, K. ET AL.: "Poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide rescues N-methyl -N-nitrosourea-induced photoreceptor cell apoptosis in Sprague-Dawley rats through preservation of nuclear factor-KB activity", EXPERIMENTAL EYE RESEARCH, vol. 84, no. 2, February 2007 (2007-02-01), pages 285 - 292 *
PAQUET-DURAND, F. ET AL.: "Excessive activation of poly(ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse", JOURNAL OF NEUROSCIENCE, vol. 27, no. 38, 19 September 2007 (2007-09-19), pages 10311 - 10319 *
SZABO, E. ET AL.: "Evidence for poly(ADP-ribose) polymerase activation in the diabetic retina", FASEB JOURNAL, vol. 15, no. 5, 2001, pages A942, 72 *
ZHENG, Y. ET AL.: "Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy", JAPANESE JOURNAL OF OPHTHALMOLOGY, vol. 47, no. 2, 2003, pages 158 - 165 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008872A1 (ja) 2011-07-13 2013-01-17 参天製薬株式会社 Ｐａｒｐ阻害活性を有する新規化合物
US9062061B2 (en) 2011-07-13 2015-06-23 Santen Pharmaceutical Co., Ltd. Compound having PARP inhibitory activity
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
US10034880B2 (en) 2014-09-11 2018-07-31 Sumitomo Dainippon Pharma Co., Ltd. Ophthalmic suspension formulation
CN104761506A (zh) * 2015-04-10 2015-07-08 温州大学 一种2-(1-苯乙烯基)喹唑啉酮化合物及其合成方法
RU2815480C1 (ru) * 2019-10-30 2024-03-18 Даимбайо. Инк. Производные изохинолинона, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с поли(АДФ-рибоза)полимеразой-1, содержащая их в качестве активного ингредиента

Also Published As

Publication number Publication date
JP2009196973A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
WO2009041566A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
NO20054855L (no) Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter derav
WO2008111497A1 (ja) トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
EP4302829A3 (en) Peptide for use in preventing or treating macular degeneration
WO2004043480A3 (en) Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa
WO2005051328A3 (en) Amelioration of macular degeneration and other ophthalmic diseases
WO2007046083A3 (en) Compositions for treatment of eye diseases
MY140611A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
CN105228989A (zh) 黄斑变性治疗中的新颖捕获剂
UA105781C2 (uk) Низькомолекулярне полісульфатоване похідне гіалуронової кислоти і лікарський засіб, який його містить
WO2008140051A1 (ja) 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
WO2009035673A8 (en) Compositions and methods for treating macular degeneration
NZ602954A (en) Inhibitors of protein tyrosine kinase activity
WO2007075720A3 (en) Topical mecamylamine formulations for ocular administration and uses thereof
CA2673751A1 (en) Protective agent for retinal nerve or optic nerve
JP2003206241A5 (ja)
WO2005055926A3 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2006094027A3 (en) Combination therapy for topical application
WO2009041565A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤
WO2009114878A3 (en) Methods and compositions for genetic and retinal disease
NO20004405L (no) Farmasøytisk sammensetning for profylakse og terapi av sykdommer forbundet med okulær-fundus-vev cytopati
WO2022096930A3 (en) Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834198

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08834198

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP